ГоловнаArchive of numbers2014Volume 22, issue 2(79)Quality of life of patients, "living with Parkinson", in aspect of  studying of a problem of pain and cognitive dei ciency
Title of the article Quality of life of patients, "living with Parkinson", in aspect of  studying of a problem of pain and cognitive dei ciency
Authors Yurov Igor Vasylovych
In the section DIAGNOSTICS AND THERAPY OF NEUROLOGICAL DISORDERS
Year 2014 Issue Volume 22, issue 2(79) Pages 55-58
Type of article Scientific article Index UDK 616.858-009.7-008.46:159.922:316.61 Index BBK -
Abstract In the conducted work we made an ef ort study the problem of pain as an early predictor Parkinson's di sease (PD), symptom in the developed clini-cal picture of PD and symptom at ac-companying somatic pathology, and also investigated cognitive violations for patients with PD.
Key words Parkinson's di sease, a  scale of UPDRS, is pain, cognitive viola tions
Access to full text version of the article pdf download
Bibliography 1. Barkhatova V.P. Neurotransmitters and extrapyramidal pathology [Neirotransmittery i ekstrapiramidnaia patologiia]. Moscow: Meditsina Publ., 1988. 175 p.
2. Vein A.M., Voznesenskaia T.G., Danilov A.B. Pain syndromes in neurological practice. [Bolevye sindromy v nevrologicheskoi praktike]. Moscow, 1999. P. 372.
3. Golubev V.L., Levin Ia.I., Vein A.M. Clinical course and pharmacotherapy of Parkinson's disease at different stages of the disease. [Osobennosti klinicheskogo techeniia i farmakoterapii bolezni Parkinsona na raznykh etapakh razvitiia zabolevaniia]. Mezhdunarodnyi meditsinskii zhurnal - International medical journal, 2005. Vol. 11, no. 4. Pp. 47-51.
4. Karaban' N.V. Complex pathogenetic therapy of Parkinson's disease. Doctor’s Thesis. [Kompleksnaia patogeneticheskaia terapiia bolezni Parkinsona (klinicheskie, diagnosticheskie, mediko-sotsial'nye aspekty): avtoref. dis. na soiskanie uch. stepeni d-ra med. nauk]. Kyiv, 2007. 33 p.
5. Kryzhanovskii G.N., Karaban' I.N., Magaeva S.V. Parkinson's disease (etiology, pathogenesis, clinical manifestations, diagnosis, treatment, prevention). [Bolezn' Parkinsona (etiologiia, patogenez, klinika, diagnostika, lechenie, profilaktika)]. Moscow: Meditsina Publ., 2002. 335 p.
6.Kryzhanovskii G.N. General pathophysiology of the nervous system. [Obshchaia patofiziologiia nervnoi sistemy]. Moscow: Meditsina Publ., 1997. 352 p.
7.Makhnev S.O. Pain syndromes in Parkinson's disease. Author’s abstract. [Bolevye sindromy pri bolezni Parkinsona: avtoref. dis. na soiskanie uch. stepeni kand. med. nauk]. Moscow, 2011. 32 p.
8. Shtok V.N., Ivanova-Smolenskaia I.A., Levin O.S. Extrapyramidal disorders: a guide to diagnosis and treatment. [Ekstrapiramidnye rasstroistva: rukovodstvo po diagnostike i lecheniiu]. Moscow: Medpress Publ., 2002. 600 p.
9. Arundinc М., Tymianski М. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium, 2003. Vol. 34. Рp. 325-337.
10. Braak H., Del Tredici К., Rub V. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 2003; 24: 197-211.
11. Croisier Е., Moran L.B., Dexter D.T. Microglial inflammation in the parkinsonian substantia nigra; relationship to a-synuclein deposition. J. Neuroinflamm., 2005. Vol. 2. Pp. 14-21.
12. De Lau L.M., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol., 2006. 5. Pp. 525-535.
13. Hartmann A., Schapira A., Agid Y. Pathophysiology of Parkinson ‘s disease. Parkinson Disorders in Clinical Practice. Blackwell Publishing Ltd., 2009. Pp. 1-10.
14. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol., 2003. Vol. 53, Suppl. 3. Pp. S26-S36. 15. Jellinger K.A. Lewy body-related alpha-synudeinopathy in the aged human brain. J. Neurоl., 2004. Vol. 111. Pp. 1219-1235.
16. Koutsilieri Е., Scheller C., Grunblatt E. Free radicals in Parkinson's disease. Ibid, 2002. Vol. 249, Suppl. 2. Pp. S1-S5.
17. Langston J.W. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann. Neurol., 2006. 59. Pp. 591-596.
18. Olanow C., Watts R., Roller W. An algorithm for the management of Parkinson's disease (2001): treatment guidelines. Neurology, 2001. Vol. 56, Suppl. 5. Pp. S1 - S88.
19. Olanow C.W., Schapira A.H., Agid Y.Neuroprotection for Parkinson's disease: prospects and promises. Ann. Neurol., 2003. Vol. 53, Suppl. 3. Pp. S1-S2.
20. Olanow C.W. Pathogenesis of cell death in Parkinson's disease. Mov. Disord., 2007. Vol. 22, Suppl. 8. Pp. S335-S342.
21. Olanow C.W., Stem M.B., Sethi K. The Scientific and Clinical Basis for the Treatment of Parkinson's Disease. Neurology, 2009. Vol. 72, Suppl. 4. Pp. S1-S136.
22. Schutz J.B., Lindenau J., Seyfried J., Dichgans J. Glutatione, oxidative stress and neurodegeneration. Eur. J. Biochem., 2000. Vol. 267. Pp. 4904-4911.
23. Schutz J.B., Lindenau J. Neurodegeneration. Ibid, 2001. Vol. 269. Pp. 3902-3910.
24. Schapira A., Olanow C.W. Neuroprotection in Parkinson's disease: myths, mysteries and misconceptions. JAMA, 2004. Vol. 29. Pp. 358-364.
25. Walter B.L., Vitek J.L. Surgical treatment for Parkinson's disease. Lancet Neurol., 2004. Vol. 3. Pp. 719-728.